Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial

Drug Safety

Volumn 38, Issue 2, 2015, Pages 189-196

  Lopez Gonzalez, Elena ^a   Herdeiro, Maria T ^b,c   Piñeiro Lamas, María ^d   Figueiras, Adolfo ^a,d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; FOLLOW UP; HEALTH PRACTITIONER; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; OUTCOME ASSESSMENT; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TEACHING; VOLUNTARY REPORTING; ORGANIZATION AND MANAGEMENT; SPAIN; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CLUSTER ANALYSIS; EDUCATION, MEDICAL, CONTINUING; HUMANS; PHARMACOVIGILANCE; SPAIN;

EID: 84925536378     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0256-6     Document Type: Article

References (28)

1. Bahri P, Arlett P. Regulatory pharmacovigilance in the European Union. In: Andrews EB, Moore N, editors. Mann’s pharmacovigilance, p. 173. London: Wiley; 2014.
2. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.
3. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union. 2010; L 348:74–99.
4. van Hunsel F, Harmark L, Pal S, Olsson S, van Grootheest K. Experiences with adverse drug reaction reporting by patients: an 11-country survey. Drug Saf. 2012;35(1):45–60. doi:10.2165/11594320-000000000-00000.
5. Gonzalez-Gonzalez C, Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Strategies to improve adverse drug reaction reporting: a critical and systematic review. Drug Saf. 2013;36(5):317–28. doi:10.1007/s40264-013-0058-2.
6. Figueiras A, Herdeiro MT, Polonia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. JAMA. 2006;296(9):1086–93. doi:10.1001/jama.296.9.1086.
7. Herdeiro MT, Polonia J, Gestal-Otero JJ, Figueiras A. Improving the reporting of adverse drug reactions: a cluster-randomized trial among pharmacists in Portugal. Drug Saf. 2008;31(4):335–44.
8. Lindquist M. The WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42:409–19.
9. The Uppsala Monitoring Centre: reporting trends. http://www.who-umc.org/DynPage.aspx?id=108476&mn1=7347&mn2=7252&mn3=7322&mn4=7558. Accessed 1st Feb 2013.
10. Herdeiro MT, Figueiras A, Polonia J, Gestal-Otero JJ. Physicians’ attitudes and adverse drug reaction reporting: a case–control study in Portugal. Drug Saf. 2005;28(9):825–33.
11. Figueiras A, Tato F, Fontainas J, Gestal-Otero JJ. Influence of physicians’ attitudes on reporting adverse drug events: a case–control study. Med Care. 1999;37(8):809–14.
12. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670–4.
13. Brown H, Prescott R. Applied mixed models in medicine. 2nd ed. Edinburgh: Wiley; 2006.
14. StataCorp. Stata statistical software: release 13.1. College Station: StataCorp LP; 2013.
15. Thomson O’Brien MA, Freemantle N, Oxman AD, Wolf F, Davis DA, Herrin J. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2001;2:CD003030. doi:10.1002/14651858.CD003030.
16. Biagi C, Montanaro N, Buccellato E, Roberto G, Vaccheri A, Motola D. Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol. 2013;69(2):237–44. doi:10.1007/s00228-012-1321-7.
17. Goldstein LH, Berlin M, Saliba W, Elias M, Berkovitch M. Founding an adverse drug reaction (ADR) network: a method for improving doctors spontaneous ADR reporting in a general hospital. J Clin Pharmacol. 2013;53(11):1220–5. doi:10.1002/jcph.149.
18. Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polonia J, Falcao A, Figueiras A. Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal. Drug Saf. 2012;35(8):655–65. doi:10.2165/11599750-000000000-00000.
19. Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. Int J Technol Assess Health Care. 2013;29(4):410–7. doi:10.1017/S0266462313000457.
20. Pedros C, Vallano A, Cereza G, Mendoza-Aran G, Agusti A, Aguilera C, et al. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians: a time series analysis in Spain. Drug Saf. 2009;32(1):77–83. doi:10.2165/00002018-200932010-00007.
21. Bracchi RC, Houghton J, Woods FJ, Thomas S, Smail SA, Routledge PA. A distance-learning programme in pharmacovigilance linked to educational credits is associated with improved reporting of suspected adverse drug reactions via the UK yellow card scheme. Br J Clin Pharmacol. 2005;60(2):221–3. doi:10.1111/j.1365-2125.2005.02419.x.
22. Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P. A novel scheme for the reporting of adverse drug reactions. Arch Dis Child. 2001;84(4):337–9.
23. Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, et al. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrenees region (PharmacoMIP) network 2-year pilot study. Drug Saf. 2010;33(5):409–16. doi:10.2165/11319170-000000000-00000.
24. Welsh CH, Pedot R, Anderson RJ. Use of morning report to enhance adverse event detection. J Gen Intern Med. 1996;11(8):454–60.
25. Consellería de Sanidade. Sistema Sanitario de Galicia. Memoria 2006. Santiago de Compostela (Spain): Xunta de Galicia, 2008. www.sergas.es. Accessed 26 June 2014.
26. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. doi:10.2165/00002018-200932010-00002.
27. Forsetlund L, Bjorndal A, Rashidian A, Jamtvedt G, O’Brien MA, Wolf F et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2009;2:CD003030. doi:10.1002/14651858.CD003030.pub2.
28. Gerritsen R, Faddegon H, Dijkers F, van Grootheest K, van Puijenbroek E. Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods. Drug Saf. 2011;34(9):755–62.